Claims for Patent: 10,479,818

Summary for Patent: 10,479,818

Title:	Immunotherapy against several tumors, such as lung cancer, including NSCLC
Abstract:	A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
Inventor(s):	Weinschenk; Toni (Aichwald, DE), Walter; Steffen (Reutlingen, DE), Fritsche; Jens (Dusslingen, DE), Song; Colette (Ostfildern, DE), Singh; Harpreet (Munich, DE)
Assignee:	IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)
Application Number:	16/444,693
Patent Claims:	1. A method of eliciting an immune response in a patient who has glioblastoma, comprising administering to the patient a composition comprising a population of activated T cells that kill the cancer cells that present a peptide consisting of the amino acid sequence SLYKGLLSV (SEQ ID NO: 56), wherein the activated T cells are produced by contacting T cells with an antigen presenting cell that presents the peptide in a complex with a human class I or II MHC molecule on the surface of the antigen presenting cell. 2. The method of claim 1, wherein the T cells are autologous to the patient. 3. The method of claim 1, wherein the T cells are obtained from a healthy donor. 4. The method of claim 1, wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells. 5. The method of claim 1, wherein the activated T cells are expanded in vitro. 6. The method of claim 1, wherein the peptide is in a complex with the class I MHC molecule. 7. The method of claim 1, wherein the antigen presenting cell is infected with recombinant virus expressing the peptide. 8. The method of claim 7, wherein the antigen presenting cell is a dendritic cell or a macrophage. 9. The method of claim 5, wherein the expansion is in the presence of an anti-CD28 antibody and IL-12. 10. The method of claim 1, wherein the population of activated T cells comprises CD8-positive cells. 11. The method of claim 1, wherein the contacting is in vitro. 12. The method of claim 1, wherein the composition further comprises an adjuvant. 13. The method of claim 12, wherein the adjuvant is selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23. 14. The method of claim 1, wherein the immune response comprises a cytotoxic T cell response. 15. The method of claim 1, wherein the class I MHC molecule is HLA-A*02. 16. The method of claim 12, wherein the adjuvant comprises IL-2. 17. The method of claim 12, wherein the adjuvant comprises IL-7. 18. The method of claim 12, wherein the adjuvant comprises IL-12. 19. The method of claim 12, wherein the adjuvant comprises IL-15. 20. The method of claim 12, wherein the adjuvant comprises IL-21.

Details for Patent 10,479,818

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2033-08-05